Roche Holding AG
RHHBYDrugs in Pipeline
419
Phase 3 Programs
257
Upcoming Catalysts
85
Next Catalyst
Mar 20, 2026
9dMarket Overview
Stock performance and key metrics
91 upcoming, 0 past
Tobemstomig Phase 2 Results Expected
Primary completion for Tobemstomig trial (NCT05645692) in Urothelial Cancer
SourceTiragolumab Phase 2 Results Expected
Primary completion for Tiragolumab trial (NCT05645692) in Urothelial Cancer
SourceAtezolizumab Phase 2 Results Expected
Primary completion for Atezolizumab trial (NCT05645692) in Urothelial Cancer
Roche discontinued Phase 2 trial recruitment and ended development of Enspryng for bone health in Duchenne muscular dystrophy patients
Source88 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Pegylated-interferon Alfa-2a
Hepatitis C, Chronic
RO7204239
Obesity
trastuzumab (Herceptin®)
Breast Cancer
mycophenolate mofetil [CellCept]
Myasthenia Gravis Generalised
Lenvatinib
Unresectable Hepatocellular Carcinoma
Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
dalcetrapib
Coronary Heart Disease
Palbociclib
Breast Cancer
Tiragolumab and Atezolizumab
Cancer
Cobimetinib
Melanoma
DMARDs
Rheumatoid Arthritis
MabThera/Rituxan
Rheumatoid Arthritis
RO7234292
Huntingtons Disease
Onartuzumab [MetMAb]
Non-Small Cell Lung Cancer
epoetin beta [NeoRecormon]
Anemia
Crovalimab
Atypical Hemolytic Uremic Syndrome
Entecavir
Pediatric Immuno-Tolerant Chronic Hepatitis B
Mosunetuzumab
Non-Hodgkin Lymphoma
Dalcetrapib (RO4607381)
Coronary Heart Disease
FEC Chemotherapy
Breast Cancer
Darbepoetin alfa
Anemia
Interferon beta-1a
Relapsing Multiple Sclerosis
Carboplatin
Breast Cancer
Etoposide
Small Cell Lung Carcinoma
Mycophenolate Mofetil
Pemphigus Vulgaris
Folic acid or folate
Rheumatoid Arthritis
Evidence-based medical care for Acute Coronary Syndrome
Coronary Heart Disease
Vincristine
Non-Hodgkin's Lymphoma
Tiragolumab
Small Cell Lung Cancer
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Anemia
methylprednisolone
Rheumatoid Arthritis
Vamikibart
Diabetic Macular Edema
Ribavirin
Hepatitis C, Chronic
Factor VIII (FVIII)
Hemophilia A
Pralsetinib
RET-fusion Non Small Cell Lung Cancer
Cabozantinib
Carcinoma, Non-Small-Cell Lung
Anti-VEGF Therapy
Neovascular Age-related Macular Degeneration
epoetin alfa or beta
Anemia
Zidovudine
HIV Infections
Remdesivir
COVID-19 Pneumonia
Polatuzumab Vedotin
Non-Hodgkin's Lymphoma
r-HuEPO
Anemia
Fingolimod
Relapsing-Remitting Multiple Sclerosis
Teriflunomide
Relapsing Multiple Sclerosis
Sefaxersen (RO7434656)
Primary IgA Nephropathy
tocilizumab [RoActemra]
Rheumatoid Arthritis
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Rheumatoid Arthritis
Tocilizumab (TCZ)
Rheumatoid Arthritis
Valganciclovir CMV Prophylaxis
Cytomegalovirus Infections
Neo-adjuvant chemotherapy
Breast Cancer
Enfuvirtide
HIV Infections
Pertuzumab
Breast Cancer
Taxane-based chemotherapy
Breast Cancer
Cyclosporine
Renal Transplantation
23-PPV
Multiple Sclerosis, Relapsing-Remitting
FAP IL2V
Cancer
Alimta or Taxotere
Non-Small Cell Lung Cancer
Oxaliplatin 130 mg/m^2
Colorectal Cancer
Non-steroidal anti-inflammatory drugs (NSAIDs)
Juvenile Idiopathic Arthritis
chlorambucil
Lymphocytic Leukemia, Chronic
5-Fluoruracil
Gastric Cancer
Giredestrant
Endometrial Cancer
Oseltamivir IV
Influenza
Sorafenib
Carcinoma, Hepatocellular
Interferon alfa 2a [Roferon]
Renal Cell Cancer
Disease-modifying anti-rheumatic drugs
Rheumatoid Arthritis
Becavizumab
Hepatocellular Carcinoma
Azathioprine
Rheumatoid Arthritis
Letrozole
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Crizotinib
Neoplasms
Bitopertin
Beta-Thalassemia
Pegylated Interferon Alfa-2a
Chronic Myelogenous Leukemia
Pembrolizumab
Non-small Cell Lung Cancer (NSCLC)
Divarasib
Non-Small Cell Lung Cancer
Rituximab SC
Non-Hodgkin's Lymphoma
saquinavir [Invirase]
HIV Infections
Optimized background antiretroviral regimen (OB)
HIV Infections
Permitted DMARDs
Rheumatoid Arthritis
Adalimumab
Ulcerative Colitis
exenatide
Diabetes Mellitus Type 2
Ocrelizumab IV
Relapsing Multiple Sclerosis
bitopertin [RO4917838] level 1
Schizophrenia
MTX
Rheumatoid Arthritis
Antipsychotics
Schizophrenia
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Hepatitis B, Chronic
Dacarbazine
Malignant Melanoma
rFVIIa
Hemophilia A
Taxotere
Breast Cancer
Fluoropyrimidine-based Chemotherapy
Colorectal Cancer
CDK4/6i
Breast Cancer
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Diabetic Retinopathy
CMF
Breast Cancer
Doxorubicin
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Stavudine
HIV Infections
temozolomide
Glioblastoma Multiforme
Ganciclovir
Cytomegalovirus Retinitis
Lamivudine
HIV Infections
PDS Implant with Ranibizumab 100 mg/mL
Neovascular Age-Related Macular Degeneration
Erlotinib
Non-Squamous Non-Small Cell Lung Cancer
satralizumab
Neuromyelitis Optica Spectrum Disorder
MMF
Lupus Nephritis
interferon-a-2a
Lymphoma
Baloxavir Marboxil
Influenza
TRO19622
Amyotrophic Lateral Sclerosis
XELOX
Colorectal Cancer
Standard adjuvant chemotherapy
Breast Cancer
DMARD
Rheumatoid Arthritis
Sunitinib
Renal Cell Carcinoma
Mycophenolate Mofetil 2 g/Day
Pemphigus Vulgaris (PV)
Lebrikizumab
Asthma
Faricimab
Wet Macular Degeneration
RO7239361
Duchenne Muscular Dystrophy
von Willebrand Factor (VWF) Concentrates
Von Willebrand Disease, Type 3
Oral Corticosteroids
Rheumatoid Arthritis
Prednisone
Lymphoma
valganciclovir [Valcyte]
Cytomegalovirus Infections
Acetaminophen/ Paracetamol
Childhood Idiopathic Nephrotic Syndrome
Corticosteroids
Breast Cancer
Antihistamine
Multiple Sclerosis
Lapatinib
Breast Cancer
epoetin
Anemia
Nab-paclitaxel
Non-Small-Cell Lung
fusidic acid [Verutex]
Non-Small Cell Lung Cancer
Risdiplam
Muscular Atrophy, Spinal
Ocrelizumab
Multiple Sclerosis
Pegylated Interferon (PEG-IFN) alfa-2a
Hepatitis D, Chronic
Enzalutamide
Prostatic Neoplasms, Castration-Resistant
oseltamivir
Influenza, Human
Gemcitabine (Chemotherapy)
Ovarian Cancer
Second-Line Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Zalcitabine
HIV Infections
Efavirenz
HIV Infections
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Etrozulimab
Ulcerative Colitis
Vinflunine
Bladder Cancer
Neoral
Kidney Transplantation
Gantenerumab
Alzheimer's Disease
PDS Implant filled with 100 mg/mL Ranibizumab
Neovascular Age-Related Macular Degeneration
Fulvestrant
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
anti-IL-2R
Kidney Transplantation
Endocrine Therapy of Physician's Choice
Early Breast Cancer
Delavirdine mesylate
HIV Infections
Chemotherapy (Induction Period)
Non-Hodgkin's Lymphoma
Fludarabine
Lymphocytic Leukemia, Chronic
tenofovir
Hepatitis D, Chronic
RO0503821 (1x/2 Weeks)
Anemia
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
Vinorelbine
Non-Small Cell Lung Cancer
bitopertin [RO4917838]
Schizophrenia
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Squamous Non-Small Cell Lung Cancer
Mycophenolate mofetil (MMF)
Lupus Nephritis
5-Fluorouracil
Gastric Cancer
Bendamustine
Chronic Lymphocytic Leukemia
Platinum chemotherapy (cisplatin or carboplatin)
Non-Squamous Non-Small Cell Lung Cancer
Irinotecan
Colorectal Cancer
Pertuzumab IV
Early Breast Cancer
Venetoclax
Chronic Lymphocytic Leukemia
RO7234292 (RG6042)
Huntington Disease
Epirubicin
Breast Cancer
Regorafenib
Colorectal Cancer
Tacrolimus
Primary Membranous Nephropathy
trastuzumab [Herceptin]
Breast Cancer
Acitretin
HIV Infections
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Ranibizumab (10 mg/mL)
Neovascular Age-related Macular Degeneration
insulin glargine
Diabetes Mellitus Type 2
Nonbiologic DMARDs of investigator's choice
Rheumatoid Arthritis
5 FU
Neoplasms
Intravitreal Ranibizumab 0.5 mg Injection
Diabetic Macular Edema
Treatment of physician's choice
Breast Cancer
Oxaliplatin
Colorectal Cancer
montelukast [Singulair]
Asthma
Non-Biologic DMARDs
Rheumatoid Arthritis
rHuPH20
Non-Small Cell Lung Cancer
Infliximab
Ulcerative Colitis
Fluorouracil
Gastric Cancer
Vemurafenib
Melanoma
Ipatasertib
Triple-Negative Breast Cancer
Ranibizumab
Diabetic Macular Edema
Emicizumab
Hemophilia A
Afimkibart
Crohns Disease
Docetaxel
Non-Small Cell Lung Cancer
tocilizumab [RoActemra/Actemra]
Rheumatoid Arthritis
Trastuzumab
Breast Cancer
Rituximab
Rheumatoid Arthritis
Atezolizumab
Carcinoma, Hepatocellular
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Anemia
erlotinib [Tarceva]
Non-Small Cell Lung Cancer
Saquinavir
HIV Infections
Obinutuzumab
Chronic Lymphocytic Leukemia (CLL)
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
Cyclophosphamide
Breast Cancer
liposomal doxorubicin
Ovarian Cancer
Omalizumab
Nasal Polyps
csDMARDs
Rheumatoid Arthritis
pertuzumab [Perjeta]
Breast Cancer
tocilizumab
Rheumatoid Arthritis
bevacizumab [Avastin]
Non-Squamous Non-Small Cell Lung Cancer
ritonavir
HIV Infections
Etrolizumab
Crohn Disease
leucovorin
Colorectal Cancer
Epoetin beta
Anemia
Lurbinectedin
Small-Cell Lung Cancer
taspoglutide
Diabetes Mellitus Type 2
Bevacizumab
Carcinoma, Hepatocellular
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-Negative Breast Cancer
Ibandronate
Post-Menopausal Osteoporosis
methotrexate
Rheumatoid Arthritis
Entrectinib
Solid Tumors
peginterferon alfa-2a [Pegasys]
Hepatitis B, Chronic
Methoxy Polyethylene Glycol-Epoetin Beta
Anemia
mycophenolate mofetil (CellCept)
Myasthenia Gravis, Generalized
Onartuzumab
Glioblastoma
Pirfenidone
Lung Diseases, Interstitial
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Carcinoma, Non-Squamous Non-Small Cell Lung
Capecitabine
Gastric Cancer
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Early Breast Cancer
Trastuzumab IV
HER2-positive Early Breast Cancer
Other Combination Anti-Cancer Therapies
Solid Tumors
Valganciclovir
Cytomegalovirus Infections
methoxy polyethylene glycol-epoetin beta [Mircera]
Anemia
Herceptin
Breast Cancer
Trastuzumab Emtansine
Breast Cancer
Gemcitabine
Pancreatic Cancer
Fenebrutinib
Relapsing Multiple Sclerosis
Dexamethasone
Idiopathic Thrombocytopenic Purpura
Glofitamab
Diffuse Large B-cell Lymphoma
Alectinib
Non-Small Cell Lung Cancer
capecitabine [Xeloda]
Colorectal Cancer
Peginterferon alfa-2a
Carcinoma, Hepatocellular
Cladribine
Lymphocytic Leukemia, Chronic
metformin
Diabetes Mellitus Type 2
ibandronate [Bonviva/Boniva]
Post-Menopausal Osteopenia
Trontinemab
Alzheimers Disease
Aflibercept
Diabetic Macular Edema
Paclitaxel
Ovarian Cancer
Sitagliptin
Diabetes Mellitus Type 2
aleglitazar
Diabetes Mellitus Type 2
Alectnib
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Non-Small Cell Lung Cancer
Inavolisib
Breast Cancer
Leucovorin (LV)
Colorectal Cancer
CHOP
Lymphoma, Large B-Cell, Diffuse
rituximab [MabThera]
Rheumatoid Arthritis
RO4917838
Schizophrenia
Baseline Treatment
Neuromyelitis Optica (NMO)
Acetaminophen/Paracetamol
Systemic Lupus Erythematosus
Phesgo
Locally Advanced or Metastatic Breast Cancer
Fludarabine Phosphate
Chronic Lymphocytic Leukemia
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Anemia
Pemetrexed
Carcinoma, Non-Small-Cell Lung
Ortho-Novum® 1/35
Rheumatoid Arthritis
PEGASYS
Hepatitis C, Chronic
Cisplatin
Nasopharyngeal Cancer
orlistat [Xenical]
Obesity
aleglitazar+metformin
Diabetes Mellitus Type 2
Dual Integrin Antagonist
Asthma
RO4917523 1.5 mg
Major Depressive Disorder
RO7247669
Melanoma
Atezolizumab Cohort 7
Solid Tumors
boceprevir
Hepatitis C, Chronic
Abemaciclib
Ovarian Cancer
enfuvirtide [Fuzeon]
HIV Infections
Tiragolumab and Atezolizumab IV FDC
PD-L1-selected Solid Tumors
RG7314
Autism Spectrum Disorder
Ro 24-7429
Sarcoma, Kaposi
Tociliuzumab
COVID-19 Pneumonia
Induction- PF-06480605 50 mg SC Q4W
Moderate to Severe Ulcerative Colitis
Bevacizumab 15 mg/kg
Advanced Liver Cancers
antibody induction
Kidney Transplantation
Onartuzumab (MetMAb)
Gastric Cancer
Standard antipsychotic therapy
Schizophrenia
RO6864018
Hepatitis B, Chronic
Semaglutide
Type 2 Diabetes Mellitus
RO7268489
Progressive Multiple Sclerosis
TCS Cream
Atopic Dermatitis
Tobemstomig
Urothelial Cancer
RO4588161
Hepatitis C, Chronic
Everolimus
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
LABA
Asthma
vismodegib
Basal Cell Carcinoma
RO4998452
Diabetes Mellitus Type 2
PEGPH20
Pancreatic Adenocarcinoma
FOLFIRI
Colorectal Cancer
PRM-151
Idiopathic Pulmonary Fibrosis
RO4602522
Alzheimer's Disease
Abiraterone
Metastatic Castration-Resistant Prostate Cancer
Mericitabine
Hepatitis C
Olaparib
Cancer of Unknown Primary Site
Induction Chemotherapy
Breast Cancer
Mircera
Anemia
AT-527
COVID-19
Zifibancimig
Macular Degeneration
Anastrozole
Early Breast Cancer
Lomustine
Glioblastoma
Actos
Diabetes Mellitus Type 2
SGN-LIV1A
Metastatic Breast Cancer
Olesoxime (TRO19622)
Chemotherapy-Induced Peripheral Neuropathy
First line chemotherapy
Mantle Cell Lymphoma
capecitabine (Xeloda®)
Breast Cancer
RO7490677
Primary Myelofibrosis
Folic Acid
Rheumatoid Arthritis
RO7126209
Alzheimers Disease
Metronidazole Actavis
Non-Squamous Non-Small Cell Lung Cancer
Tominersen
Huntington Disease
RO5217790
Cervical Intraepithelial Neoplasia
Mycophenolate Mofetil/Mycophenolic Acid
Lupus Nephritis
RO5313534
Alzheimer's Disease
TRO40303
Acute Myocardial Infarctus
Epidoxorubicin
Breast Cancer
Balovaptan
Stress Disorders, Post-Traumatic
Carboplatin-based chemotherapy
Non-Small Cell Lung Cancer
Pegylated Interferon (Peginterferon) Alfa-2a
Hepatitis B, Chronic
Pravastatin
Dyslipidemia
Lomvastomig
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
RG3421 120mg
Psoriasis
Doxycline
Non-Small Cell Lung Cancer
Standard taxane therapy
Breast Cancer
obinutuzumab (RO5072759)
Non-Hodgkin's Lymphoma
Iberdomide
Multiple Myeloma
Ifosfamide
Mature B-Cell Non-Hodgkin Lymphoma
RO6889450
Schizophrenia, Schizoaffective Disorder
GC33
Carcinoma, Hepatocellular
RO4917523
Fragile X Syndrome
fluorouracil (5FU)
Colorectal Cancer
Erlotinib, escalating dose
Pancreatic Cancer
pralsetinib (BLU-667)
RET-altered Non Small Cell Lung Cancer
ibandronate [Bondronat]
Pain; Bone Neoplasms; Neoplasm Metastasis
RO4876904
Diabetes Mellitus Type 2
Crenezumab
Alzheimer Disease
5-FU
Colorectal Cancer
Sham Procedure
Neovascularization, Choroidal
Cevostamab
Multiple Myeloma
ANA598
HCV Infection
Copegus
Hepatitis C, Chronic
N-acetylcysteine
Idiopathic Pulmonary Fibrosis
OpRegen
Age-Related Macular Degeneration
RO4917523 0.5 mg
Fragile X Syndrome
eloxatin
Colorectal Cancer
Basmisanil
Schizophrenia
RO7795081
Obesity or Overweight
RO4995819
Major Depressive Disorder
RG7774
Diabetic Retinopathy
Forimtamig
Relapsed or Refractory Multiple Myeloma
P38 Inhibitor (4) 150mg
Rheumatoid Arthritis
RO5190591 (Danoprevir)
Hepatitis C, Chronic
Standard chemotherapy
Breast Cancer
Experimental
Diabetic Neuropathy
fotemustine
Glioblastoma Multiforme
Investigator's choice of anti-cancer treatment (except immunotherapy)
Breast Cancer
Inhaled corticposteroids (ICS)
Asthma
Lenalidomide
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Englumafusp alfa
Lymphoma, Non-Hodgkin
Trastuzumab emtansine [Kadcyla]
Breast Cancer
Atezolizumab [TECENTRIQ]
Lymphoma
Optimized Background ARVs
HIV Infections
Taxane (docetaxel or paclitaxel)
Breast Cancer
RO5190591
Hepatitis C, Chronic
Temozolomide (TMZ)
High Grade Glioma
Sildenafil
Idiopathic Pulmonary Fibrosis
Abacavir sulfate
HIV Infections
5-Fluorouracil (5-FU)
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
ZN-A-1041
Advanced Solid Tumors
RAR Gamma
Emphysema
NXT007
Hemophilia A
RO5459072
Sjogren's Syndrome
Alogabat
Angelman Syndrome
89Zr-Df-IAB22M2C
Non-Hodgkins Lymphoma
beta-lactam
Soft Tissue Infections
RO5185426
Malignant Melanoma
Mosunetuzumab Intravenous (IV)
Diffuse Large B-cell Lymphoma
RG1662
Down Syndrome
Rituxumab
B-cell Non-Hodgkin Lymphoma
RO4905417
Coronary Heart Disease, Graft Occlusion, Vascular
Ribociclib
Breast Cancer
RO7269162
Alzheimer's Disease
Ocrelizumab Test Formulation
Multiple Sclerosis
Xeloda
Breast Cancer
C.E.R.A.
Anemia
cetuximab
Multiple Myeloma, Neoplasms
Polatuzumab vedotin (Liquid)
Lymphoma
Mosunetuzumab (IV)
B-cell Non-Hodgkin Lymphoma
RO7247669 2100 mg
Melanoma
Taspoglutide 20mg
Diabetes Mellitus Type 2
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Metastatic Breast Cancer
RO6958688
Carcinoma, Non-Small-Cell Lung
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Breast Neoplasms
RO4929097
Non-Squamous Non-Small Cell Lung Cancer
Folinic Acid
Rectal Cancer
Enfortumab Vedotin
Urothelial Carcinoma
Autogene Cevumeran
Muscle-invasive Urothelial Carcinoma
SSRI
Obsessive-Compulsive Disorder
Epothilone D
Breast Cancer
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
HER2-Positive Early Breast Cancer
Interferon alfa-2a
Renal Cell Cancer
Levofolinic acid
Colorectal Cancer
P38 Inhibitor (4)
Rheumatoid Arthritis
Ceftriaxone
Pneumonia, Bacterial
GK Activator (2)
Diabetes Mellitus Type 2
Olesoxime
Muscular Atrophy, Spinal
Axitinib
Renal Cell Carcinoma
Second line chemotherapy
Breast Cancer
danoprevir + ritonavir
Hepatitis C, Chronic
Rituximab IV
Lymphoma, Large B-Cell, Diffuse
Atezolizumab (MPDL3280A) [TECENTRIQ]
Lymphoma, Follicular
Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
RO7046015
Parkinson's Disease
Aromatase Inhibitor
Breast Cancer
DPP-IV Inhibitor
Diabetes Mellitus Type 2
PEGASYS [peginterferon alfa-2a]
Hepatitis B, Chronic
MSTT1041A
Asthma
RO7017773
Autism Spectrum Disorder (ASD)
RO 205-2349
Diabetes
Danoprevir
Hepatitis C, Chronic
Diphenhydramine hydrochloride (HCl)
Lupus Nephritis
RO5024048
Hepatitis C, Chronic
Hormonal Therapy
Breast Cancer
Prasinezumab
Parkinsons Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pegylated-interferon Alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
RO7204239 | Phase 3 | Obesity | - | - |
trastuzumab (Herceptin®) | Phase 3 | Breast Cancer | - | - |
mycophenolate mofetil [CellCept] | Phase 3 | Myasthenia Gravis Generalised | - | - |
Lenvatinib | Phase 3 | Unresectable Hepatocellular Carcinoma | - | - |
Eculizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
dalcetrapib | Phase 3 | Coronary Heart Disease | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
Tiragolumab and Atezolizumab | Phase 3 | Cancer | - | - |
Cobimetinib | Phase 3 | Melanoma | - | - |
DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
MabThera/Rituxan | Phase 3 | Rheumatoid Arthritis | - | - |
RO7234292 | Phase 3 | Huntingtons Disease | - | - |
Onartuzumab [MetMAb] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
epoetin beta [NeoRecormon] | Phase 3 | Anemia | - | - |
Crovalimab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - | - |
Entecavir | Phase 3 | Pediatric Immuno-Tolerant Chronic Hepatitis B | - | - |
Mosunetuzumab | Phase 3 | Non-Hodgkin Lymphoma | - | - |
Dalcetrapib (RO4607381) | Phase 3 | Coronary Heart Disease | - | - |
FEC Chemotherapy | Phase 3 | Breast Cancer | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
Interferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Carboplatin | Phase 3 | Breast Cancer | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Mycophenolate Mofetil | Phase 3 | Pemphigus Vulgaris | - | - |
Folic acid or folate | Phase 3 | Rheumatoid Arthritis | - | - |
Evidence-based medical care for Acute Coronary Syndrome | Phase 3 | Coronary Heart Disease | - | - |
Vincristine | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Tiragolumab | Phase 3 | Small Cell Lung Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Phase 3 | Anemia | - | - |
methylprednisolone | Phase 3 | Rheumatoid Arthritis | - | - |
Vamikibart | Phase 3 | Diabetic Macular Edema | - | - |
Ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
Factor VIII (FVIII) | Phase 3 | Hemophilia A | - | - |
Pralsetinib | Phase 3 | RET-fusion Non Small Cell Lung Cancer | - | - |
Cabozantinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Anti-VEGF Therapy | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
epoetin alfa or beta | Phase 3 | Anemia | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Remdesivir | Phase 3 | COVID-19 Pneumonia | - | - |
Polatuzumab Vedotin | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
r-HuEPO | Phase 3 | Anemia | - | - |
Fingolimod | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Sefaxersen (RO7434656) | Phase 3 | Primary IgA Nephropathy | - | - |
tocilizumab [RoActemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab (TCZ) | Phase 3 | Rheumatoid Arthritis | - | - |
Valganciclovir CMV Prophylaxis | Phase 3 | Cytomegalovirus Infections | - | - |
Neo-adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
Enfuvirtide | Phase 3 | HIV Infections | - | - |
Pertuzumab | Phase 3 | Breast Cancer | - | - |
Taxane-based chemotherapy | Phase 3 | Breast Cancer | - | - |
Cyclosporine | Phase 3 | Renal Transplantation | - | - |
23-PPV | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
FAP IL2V | Phase 3 | Cancer | - | - |
Alimta or Taxotere | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Oxaliplatin 130 mg/m^2 | Phase 3 | Colorectal Cancer | - | - |
Non-steroidal anti-inflammatory drugs (NSAIDs) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
5-Fluoruracil | Phase 3 | Gastric Cancer | - | - |
Giredestrant | Phase 3 | Endometrial Cancer | - | - |
Oseltamivir IV | Phase 3 | Influenza | - | - |
Sorafenib | Phase 3 | Carcinoma, Hepatocellular | - | - |
Interferon alfa 2a [Roferon] | Phase 3 | Renal Cell Cancer | - | - |
Disease-modifying anti-rheumatic drugs | Phase 3 | Rheumatoid Arthritis | - | - |
Becavizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Azathioprine | Phase 3 | Rheumatoid Arthritis | - | - |
Letrozole | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | - | - |
Crizotinib | Phase 3 | Neoplasms | - | - |
Bitopertin | Phase 3 | Beta-Thalassemia | - | - |
Pegylated Interferon Alfa-2a | Phase 3 | Chronic Myelogenous Leukemia | - | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Divarasib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Rituximab SC | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
saquinavir [Invirase] | Phase 3 | HIV Infections | - | - |
Optimized background antiretroviral regimen (OB) | Phase 3 | HIV Infections | - | - |
Permitted DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
Adalimumab | Phase 3 | Ulcerative Colitis | - | - |
exenatide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Ocrelizumab IV | Phase 3 | Relapsing Multiple Sclerosis | - | - |
bitopertin [RO4917838] level 1 | Phase 3 | Schizophrenia | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
Antipsychotics | Phase 3 | Schizophrenia | - | - |
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg | Phase 3 | Hepatitis B, Chronic | - | - |
Dacarbazine | Phase 3 | Malignant Melanoma | - | - |
rFVIIa | Phase 3 | Hemophilia A | - | - |
Taxotere | Phase 3 | Breast Cancer | - | - |
Fluoropyrimidine-based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
CDK4/6i | Phase 3 | Breast Cancer | - | - |
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | Phase 3 | Diabetic Retinopathy | - | - |
CMF | Phase 3 | Breast Cancer | - | - |
Doxorubicin | Phase 3 | Diffuse Large B-Cell Lymphoma, Lymphoma Follicular | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
temozolomide | Phase 3 | Glioblastoma Multiforme | - | - |
Ganciclovir | Phase 3 | Cytomegalovirus Retinitis | - | - |
Lamivudine | Phase 3 | HIV Infections | - | - |
PDS Implant with Ranibizumab 100 mg/mL | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Erlotinib | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
satralizumab | Phase 3 | Neuromyelitis Optica Spectrum Disorder | - | - |
MMF | Phase 3 | Lupus Nephritis | - | - |
interferon-a-2a | Phase 3 | Lymphoma | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
TRO19622 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
XELOX | Phase 3 | Colorectal Cancer | - | - |
Standard adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
DMARD | Phase 3 | Rheumatoid Arthritis | - | - |
Sunitinib | Phase 3 | Renal Cell Carcinoma | - | - |
Mycophenolate Mofetil 2 g/Day | Phase 3 | Pemphigus Vulgaris (PV) | - | - |
Lebrikizumab | Phase 3 | Asthma | - | - |
Faricimab | Phase 3 | Wet Macular Degeneration | - | - |
RO7239361 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
von Willebrand Factor (VWF) Concentrates | Phase 3 | Von Willebrand Disease, Type 3 | - | - |
Oral Corticosteroids | Phase 3 | Rheumatoid Arthritis | - | - |
Prednisone | Phase 3 | Lymphoma | - | - |
valganciclovir [Valcyte] | Phase 3 | Cytomegalovirus Infections | - | - |
Acetaminophen/ Paracetamol | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | - | - |
Corticosteroids | Phase 3 | Breast Cancer | - | - |
Antihistamine | Phase 3 | Multiple Sclerosis | - | - |
Lapatinib | Phase 3 | Breast Cancer | - | - |
epoetin | Phase 3 | Anemia | - | - |
Nab-paclitaxel | Phase 3 | Non-Small-Cell Lung | - | - |
fusidic acid [Verutex] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Risdiplam | Phase 3 | Muscular Atrophy, Spinal | - | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - | - |
Pegylated Interferon (PEG-IFN) alfa-2a | Phase 3 | Hepatitis D, Chronic | - | - |
Enzalutamide | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - | - |
oseltamivir | Phase 3 | Influenza, Human | - | - |
Gemcitabine (Chemotherapy) | Phase 3 | Ovarian Cancer | - | - |
Second-Line Chemotherapy | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Zalcitabine | Phase 3 | HIV Infections | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | - | - |
Etrozulimab | Phase 3 | Ulcerative Colitis | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Neoral | Phase 3 | Kidney Transplantation | - | - |
Gantenerumab | Phase 3 | Alzheimer's Disease | - | - |
PDS Implant filled with 100 mg/mL Ranibizumab | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Fulvestrant | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | - | - |
anti-IL-2R | Phase 3 | Kidney Transplantation | - | - |
Endocrine Therapy of Physician's Choice | Phase 3 | Early Breast Cancer | - | - |
Delavirdine mesylate | Phase 3 | HIV Infections | - | - |
Chemotherapy (Induction Period) | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Fludarabine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
tenofovir | Phase 3 | Hepatitis D, Chronic | - | - |
RO0503821 (1x/2 Weeks) | Phase 3 | Anemia | - | - |
Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Vinorelbine | Phase 3 | Non-Small Cell Lung Cancer | - | - |
bitopertin [RO4917838] | Phase 3 | Schizophrenia | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody | Phase 3 | Squamous Non-Small Cell Lung Cancer | - | - |
Mycophenolate mofetil (MMF) | Phase 3 | Lupus Nephritis | - | - |
5-Fluorouracil | Phase 3 | Gastric Cancer | - | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Platinum chemotherapy (cisplatin or carboplatin) | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Irinotecan | Phase 3 | Colorectal Cancer | - | - |
Pertuzumab IV | Phase 3 | Early Breast Cancer | - | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
RO7234292 (RG6042) | Phase 3 | Huntington Disease | - | - |
Epirubicin | Phase 3 | Breast Cancer | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
trastuzumab [Herceptin] | Phase 3 | Breast Cancer | - | - |
Acitretin | Phase 3 | HIV Infections | - | - |
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) | Phase 3 | Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | - | - |
Ranibizumab (10 mg/mL) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
insulin glargine | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Nonbiologic DMARDs of investigator's choice | Phase 3 | Rheumatoid Arthritis | - | - |
5 FU | Phase 3 | Neoplasms | - | - |
Intravitreal Ranibizumab 0.5 mg Injection | Phase 3 | Diabetic Macular Edema | - | - |
Treatment of physician's choice | Phase 3 | Breast Cancer | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
montelukast [Singulair] | Phase 3 | Asthma | - | - |
Non-Biologic DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
rHuPH20 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Infliximab | Phase 3 | Ulcerative Colitis | - | - |
Fluorouracil | Phase 3 | Gastric Cancer | - | - |
Vemurafenib | Phase 3 | Melanoma | - | - |
Ipatasertib | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ranibizumab | Phase 3 | Diabetic Macular Edema | - | - |
Emicizumab | Phase 3 | Hemophilia A | - | - |
Afimkibart | Phase 3 | Crohns Disease | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Trastuzumab | Phase 3 | Breast Cancer | - | - |
Rituximab | Phase 3 | Rheumatoid Arthritis | - | - |
Atezolizumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.) | Phase 3 | Anemia | - | - |
erlotinib [Tarceva] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Saquinavir | Phase 3 | HIV Infections | - | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - | - |
Cyclophosphamide | Phase 3 | Breast Cancer | - | - |
liposomal doxorubicin | Phase 3 | Ovarian Cancer | - | - |
Omalizumab | Phase 3 | Nasal Polyps | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
pertuzumab [Perjeta] | Phase 3 | Breast Cancer | - | - |
tocilizumab | Phase 3 | Rheumatoid Arthritis | - | - |
bevacizumab [Avastin] | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
ritonavir | Phase 3 | HIV Infections | - | - |
Etrolizumab | Phase 3 | Crohn Disease | - | - |
leucovorin | Phase 3 | Colorectal Cancer | - | - |
Epoetin beta | Phase 3 | Anemia | - | - |
Lurbinectedin | Phase 3 | Small-Cell Lung Cancer | - | - |
taspoglutide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Bevacizumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ibandronate | Phase 3 | Post-Menopausal Osteoporosis | - | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Entrectinib | Phase 3 | Solid Tumors | - | - |
peginterferon alfa-2a [Pegasys] | Phase 3 | Hepatitis B, Chronic | - | - |
Methoxy Polyethylene Glycol-Epoetin Beta | Phase 3 | Anemia | - | - |
mycophenolate mofetil (CellCept) | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Onartuzumab | Phase 3 | Glioblastoma | - | - |
Pirfenidone | Phase 3 | Lung Diseases, Interstitial | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Carcinoma, Non-Squamous Non-Small Cell Lung | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) | Phase 3 | Early Breast Cancer | - | - |
Trastuzumab IV | Phase 3 | HER2-positive Early Breast Cancer | - | - |
Other Combination Anti-Cancer Therapies | Phase 3 | Solid Tumors | - | - |
Valganciclovir | Phase 3 | Cytomegalovirus Infections | - | - |
methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 3 | Anemia | - | - |
Herceptin | Phase 3 | Breast Cancer | - | - |
Trastuzumab Emtansine | Phase 3 | Breast Cancer | - | - |
Gemcitabine | Phase 3 | Pancreatic Cancer | - | - |
Fenebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Dexamethasone | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
Glofitamab | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
capecitabine [Xeloda] | Phase 3 | Colorectal Cancer | - | - |
Peginterferon alfa-2a | Phase 3 | Carcinoma, Hepatocellular | - | - |
Cladribine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Post-Menopausal Osteopenia | - | - |
Trontinemab | Phase 3 | Alzheimers Disease | - | - |
Aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Paclitaxel | Phase 3 | Ovarian Cancer | - | - |
Sitagliptin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Alectnib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Inavolisib | Phase 3 | Breast Cancer | - | - |
Leucovorin (LV) | Phase 3 | Colorectal Cancer | - | - |
CHOP | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
rituximab [MabThera] | Phase 3 | Rheumatoid Arthritis | - | - |
RO4917838 | Phase 3 | Schizophrenia | - | - |
Baseline Treatment | Phase 3 | Neuromyelitis Optica (NMO) | - | - |
Acetaminophen/Paracetamol | Phase 3 | Systemic Lupus Erythematosus | - | - |
Phesgo | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - | - |
Fludarabine Phosphate | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
methoxy polyethylene glycol-epoetin beta [C.E.R.A.] | Phase 3 | Anemia | - | - |
Pemetrexed | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Ortho-Novum® 1/35 | Phase 3 | Rheumatoid Arthritis | - | - |
PEGASYS | Phase 3 | Hepatitis C, Chronic | - | - |
Cisplatin | Phase 3 | Nasopharyngeal Cancer | - | - |
orlistat [Xenical] | Phase 3 | Obesity | - | - |
aleglitazar+metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Dual Integrin Antagonist | Phase 2 | Asthma | - | - |
RO4917523 1.5 mg | Phase 2 | Major Depressive Disorder | - | - |
RO7247669 | Phase 2 | Melanoma | - | - |
Atezolizumab Cohort 7 | Phase 2 | Solid Tumors | - | - |
boceprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Abemaciclib | Phase 2 | Ovarian Cancer | - | - |
enfuvirtide [Fuzeon] | Phase 2 | HIV Infections | - | - |
Tiragolumab and Atezolizumab IV FDC | Phase 2 | PD-L1-selected Solid Tumors | - | - |
RG7314 | Phase 2 | Autism Spectrum Disorder | - | - |
Ro 24-7429 | Phase 2 | Sarcoma, Kaposi | - | - |
Tociliuzumab | Phase 2 | COVID-19 Pneumonia | - | - |
Induction- PF-06480605 50 mg SC Q4W | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Bevacizumab 15 mg/kg | Phase 2 | Advanced Liver Cancers | - | - |
antibody induction | Phase 2 | Kidney Transplantation | - | - |
Onartuzumab (MetMAb) | Phase 2 | Gastric Cancer | - | - |
Standard antipsychotic therapy | Phase 2 | Schizophrenia | - | - |
RO6864018 | Phase 2 | Hepatitis B, Chronic | - | - |
Semaglutide | Phase 2 | Type 2 Diabetes Mellitus | - | - |
RO7268489 | Phase 2 | Progressive Multiple Sclerosis | - | - |
TCS Cream | Phase 2 | Atopic Dermatitis | - | - |
Tobemstomig | Phase 2 | Urothelial Cancer | - | - |
RO4588161 | Phase 2 | Hepatitis C, Chronic | - | - |
Everolimus | Phase 2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | - | - |
LABA | Phase 2 | Asthma | - | - |
vismodegib | Phase 2 | Basal Cell Carcinoma | - | - |
RO4998452 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
PEGPH20 | Phase 2 | Pancreatic Adenocarcinoma | - | - |
FOLFIRI | Phase 2 | Colorectal Cancer | - | - |
PRM-151 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
RO4602522 | Phase 2 | Alzheimer's Disease | - | - |
Abiraterone | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Mericitabine | Phase 2 | Hepatitis C | - | - |
Olaparib | Phase 2 | Cancer of Unknown Primary Site | - | - |
Induction Chemotherapy | Phase 2 | Breast Cancer | - | - |
Mircera | Phase 2 | Anemia | - | - |
AT-527 | Phase 2 | COVID-19 | - | - |
Zifibancimig | Phase 2 | Macular Degeneration | - | - |
Anastrozole | Phase 2 | Early Breast Cancer | - | - |
Lomustine | Phase 2 | Glioblastoma | - | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - | - |
SGN-LIV1A | Phase 2 | Metastatic Breast Cancer | - | - |
Olesoxime (TRO19622) | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | - | - |
First line chemotherapy | Phase 2 | Mantle Cell Lymphoma | - | - |
capecitabine (Xeloda®) | Phase 2 | Breast Cancer | - | - |
RO7490677 | Phase 2 | Primary Myelofibrosis | - | - |
Folic Acid | Phase 2 | Rheumatoid Arthritis | - | - |
RO7126209 | Phase 2 | Alzheimers Disease | - | - |
Metronidazole Actavis | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Tominersen | Phase 2 | Huntington Disease | - | - |
RO5217790 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
Mycophenolate Mofetil/Mycophenolic Acid | Phase 2 | Lupus Nephritis | - | - |
RO5313534 | Phase 2 | Alzheimer's Disease | - | - |
TRO40303 | Phase 2 | Acute Myocardial Infarctus | - | - |
Epidoxorubicin | Phase 2 | Breast Cancer | - | - |
Balovaptan | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
Carboplatin-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Pegylated Interferon (Peginterferon) Alfa-2a | Phase 2 | Hepatitis B, Chronic | - | - |
Pravastatin | Phase 2 | Dyslipidemia | - | - |
Lomvastomig | Phase 2 | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | - | - |
RG3421 120mg | Phase 2 | Psoriasis | - | - |
Doxycline | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Standard taxane therapy | Phase 2 | Breast Cancer | - | - |
obinutuzumab (RO5072759) | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Iberdomide | Phase 2 | Multiple Myeloma | - | - |
Ifosfamide | Phase 2 | Mature B-Cell Non-Hodgkin Lymphoma | - | - |
RO6889450 | Phase 2 | Schizophrenia, Schizoaffective Disorder | - | - |
GC33 | Phase 2 | Carcinoma, Hepatocellular | - | - |
RO4917523 | Phase 2 | Fragile X Syndrome | - | - |
fluorouracil (5FU) | Phase 2 | Colorectal Cancer | - | - |
Erlotinib, escalating dose | Phase 2 | Pancreatic Cancer | - | - |
pralsetinib (BLU-667) | Phase 2 | RET-altered Non Small Cell Lung Cancer | - | - |
ibandronate [Bondronat] | Phase 2 | Pain; Bone Neoplasms; Neoplasm Metastasis | - | - |
RO4876904 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Crenezumab | Phase 2 | Alzheimer Disease | - | - |
5-FU | Phase 2 | Colorectal Cancer | - | - |
Sham Procedure | Phase 2 | Neovascularization, Choroidal | - | - |
Cevostamab | Phase 2 | Multiple Myeloma | - | - |
ANA598 | Phase 2 | HCV Infection | - | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - | - |
N-acetylcysteine | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
OpRegen | Phase 2 | Age-Related Macular Degeneration | - | - |
RO4917523 0.5 mg | Phase 2 | Fragile X Syndrome | - | - |
eloxatin | Phase 2 | Colorectal Cancer | - | - |
Basmisanil | Phase 2 | Schizophrenia | - | - |
RO7795081 | Phase 2 | Obesity or Overweight | - | - |
RO4995819 | Phase 2 | Major Depressive Disorder | - | - |
RG7774 | Phase 2 | Diabetic Retinopathy | - | - |
Forimtamig | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
P38 Inhibitor (4) 150mg | Phase 2 | Rheumatoid Arthritis | - | - |
RO5190591 (Danoprevir) | Phase 2 | Hepatitis C, Chronic | - | - |
Standard chemotherapy | Phase 2 | Breast Cancer | - | - |
Experimental | Phase 2 | Diabetic Neuropathy | - | - |
fotemustine | Phase 2 | Glioblastoma Multiforme | - | - |
Investigator's choice of anti-cancer treatment (except immunotherapy) | Phase 2 | Breast Cancer | - | - |
Inhaled corticposteroids (ICS) | Phase 2 | Asthma | - | - |
Lenalidomide | Phase 2 | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | - | - |
Englumafusp alfa | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Trastuzumab emtansine [Kadcyla] | Phase 2 | Breast Cancer | - | - |
Atezolizumab [TECENTRIQ] | Phase 2 | Lymphoma | - | - |
Optimized Background ARVs | Phase 2 | HIV Infections | - | - |
Taxane (docetaxel or paclitaxel) | Phase 2 | Breast Cancer | - | - |
RO5190591 | Phase 2 | Hepatitis C, Chronic | - | - |
Temozolomide (TMZ) | Phase 2 | High Grade Glioma | - | - |
Sildenafil | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
5-Fluorouracil (5-FU) | Phase 2 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | - | - |
ZN-A-1041 | Phase 2 | Advanced Solid Tumors | - | - |
RAR Gamma | Phase 2 | Emphysema | - | - |
NXT007 | Phase 2 | Hemophilia A | - | - |
RO5459072 | Phase 2 | Sjogren's Syndrome | - | - |
Alogabat | Phase 2 | Angelman Syndrome | - | - |
89Zr-Df-IAB22M2C | Phase 2 | Non-Hodgkins Lymphoma | - | - |
beta-lactam | Phase 2 | Soft Tissue Infections | - | - |
RO5185426 | Phase 2 | Malignant Melanoma | - | - |
Mosunetuzumab Intravenous (IV) | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
RG1662 | Phase 2 | Down Syndrome | - | - |
Rituxumab | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
RO4905417 | Phase 2 | Coronary Heart Disease, Graft Occlusion, Vascular | - | - |
Ribociclib | Phase 2 | Breast Cancer | - | - |
RO7269162 | Phase 2 | Alzheimer's Disease | - | - |
Ocrelizumab Test Formulation | Phase 2 | Multiple Sclerosis | - | - |
Xeloda | Phase 2 | Breast Cancer | - | - |
C.E.R.A. | Phase 2 | Anemia | - | - |
cetuximab | Phase 2 | Multiple Myeloma, Neoplasms | - | - |
Polatuzumab vedotin (Liquid) | Phase 2 | Lymphoma | - | - |
Mosunetuzumab (IV) | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
RO7247669 2100 mg | Phase 2 | Melanoma | - | - |
Taspoglutide 20mg | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg | Phase 2 | Metastatic Breast Cancer | - | - |
RO6958688 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody | Phase 2 | Breast Neoplasms | - | - |
RO4929097 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Folinic Acid | Phase 2 | Rectal Cancer | - | - |
Enfortumab Vedotin | Phase 2 | Urothelial Carcinoma | - | - |
Autogene Cevumeran | Phase 2 | Muscle-invasive Urothelial Carcinoma | - | - |
SSRI | Phase 2 | Obsessive-Compulsive Disorder | - | - |
Epothilone D | Phase 2 | Breast Cancer | - | - |
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC) | Phase 2 | HER2-Positive Early Breast Cancer | - | - |
Interferon alfa-2a | Phase 2 | Renal Cell Cancer | - | - |
Levofolinic acid | Phase 2 | Colorectal Cancer | - | - |
P38 Inhibitor (4) | Phase 2 | Rheumatoid Arthritis | - | - |
Ceftriaxone | Phase 2 | Pneumonia, Bacterial | - | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Olesoxime | Phase 2 | Muscular Atrophy, Spinal | - | - |
Axitinib | Phase 2 | Renal Cell Carcinoma | - | - |
Second line chemotherapy | Phase 2 | Breast Cancer | - | - |
danoprevir + ritonavir | Phase 2 | Hepatitis C, Chronic | - | - |
Rituximab IV | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ] | Phase 2 | Lymphoma, Follicular | - | - |
Fulvestrant or an Aromatase Inhibitor (Physician Choice) | Phase 2 | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | - | - |
RO7046015 | Phase 2 | Parkinson's Disease | - | - |
Aromatase Inhibitor | Phase 2 | Breast Cancer | - | - |
DPP-IV Inhibitor | Phase 2 | Diabetes Mellitus Type 2 | - | - |
PEGASYS [peginterferon alfa-2a] | Phase 2 | Hepatitis B, Chronic | - | - |
MSTT1041A | Phase 2 | Asthma | - | - |
RO7017773 | Phase 2 | Autism Spectrum Disorder (ASD) | - | - |
RO 205-2349 | Phase 2 | Diabetes | - | - |
Danoprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Diphenhydramine hydrochloride (HCl) | Phase 2 | Lupus Nephritis | - | - |
RO5024048 | Phase 2 | Hepatitis C, Chronic | - | - |
Hormonal Therapy | Phase 2 | Breast Cancer | - | - |
Prasinezumab | Phase 2 | Parkinsons Disease | - | - |
Breast Cancer
1 drug in this indication
Duchenne Muscular Dystrophy
1 drug in this indication
Obesity
1 drug in this indication
Myasthenia Gravis Generalised
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)